 Micol Rothman
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 10 | 2023 | 242 | 3.860 |
Why?
| | Transgender Persons | 7 | 2025 | 203 | 2.660 |
Why?
| | Osteoporotic Fractures | 5 | 2024 | 61 | 2.460 |
Why?
| | Bone Density Conservation Agents | 9 | 2024 | 83 | 2.200 |
Why?
| | Estradiol | 5 | 2025 | 524 | 1.300 |
Why?
| | Transsexualism | 2 | 2021 | 20 | 1.280 |
Why?
| | Absorptiometry, Photon | 5 | 2023 | 268 | 1.270 |
Why?
| | Bone Density | 6 | 2022 | 499 | 1.030 |
Why?
| | Bone Diseases, Metabolic | 3 | 2024 | 64 | 1.020 |
Why?
| | Hyperandrogenism | 2 | 2021 | 21 | 1.010 |
Why?
| | Testosterone | 6 | 2025 | 418 | 0.860 |
Why?
| | Postmenopause | 4 | 2021 | 371 | 0.740 |
Why?
| | Interdisciplinary Placement | 1 | 2020 | 2 | 0.650 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.620 |
Why?
| | Telecommunications | 1 | 2019 | 21 | 0.610 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 240 | 0.600 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 128 | 0.590 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1552 | 0.590 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 346 | 0.490 |
Why?
| | Diphosphonates | 2 | 2019 | 69 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 375 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.440 |
Why?
| | Quality Improvement | 1 | 2023 | 1255 | 0.440 |
Why?
| | Hypogonadism | 3 | 2013 | 92 | 0.440 |
Why?
| | Denosumab | 3 | 2024 | 9 | 0.430 |
Why?
| | Mass Media | 1 | 2014 | 40 | 0.420 |
Why?
| | Glucocorticoids | 3 | 2024 | 535 | 0.410 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2024 | 42 | 0.400 |
Why?
| | Estrone | 2 | 2010 | 40 | 0.370 |
Why?
| | Spinal Fractures | 2 | 2024 | 74 | 0.360 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 278 | 0.340 |
Why?
| | Humans | 38 | 2025 | 142526 | 0.340 |
Why?
| | Telemedicine | 1 | 2020 | 911 | 0.340 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 8 | 0.330 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 44 | 0.330 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2013 | 184 | 0.330 |
Why?
| | Facial Bones | 1 | 2010 | 30 | 0.330 |
Why?
| | Mass Screening | 2 | 2021 | 1325 | 0.320 |
Why?
| | Injections, Subcutaneous | 3 | 2025 | 164 | 0.320 |
Why?
| | Injections, Intramuscular | 3 | 2025 | 141 | 0.320 |
Why?
| | Menstrual Cycle | 1 | 2010 | 139 | 0.310 |
Why?
| | Skull | 1 | 2010 | 151 | 0.300 |
Why?
| | Gender Identity | 2 | 2021 | 130 | 0.300 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2024 | 197 | 0.290 |
Why?
| | Female | 22 | 2025 | 76624 | 0.280 |
Why?
| | Infertility | 1 | 2007 | 55 | 0.260 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 31 | 0.260 |
Why?
| | Male | 21 | 2025 | 70910 | 0.250 |
Why?
| | Ovary | 1 | 2008 | 226 | 0.240 |
Why?
| | Adult | 16 | 2025 | 39715 | 0.240 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2007 | 213 | 0.230 |
Why?
| | Hypoparathyroidism | 1 | 2025 | 7 | 0.230 |
Why?
| | Bone Remodeling | 1 | 2024 | 77 | 0.210 |
Why?
| | Adrenal Insufficiency | 1 | 2024 | 29 | 0.200 |
Why?
| | Thromboembolism | 1 | 2024 | 126 | 0.190 |
Why?
| | Cohort Studies | 2 | 2023 | 5858 | 0.190 |
Why?
| | Brain Injuries | 1 | 2007 | 505 | 0.180 |
Why?
| | Androgens | 2 | 2013 | 190 | 0.170 |
Why?
| | Academic Medical Centers | 1 | 2023 | 531 | 0.170 |
Why?
| | Hydrocortisone | 2 | 2024 | 310 | 0.160 |
Why?
| | Aged | 9 | 2025 | 25117 | 0.160 |
Why?
| | Teriparatide | 3 | 2025 | 9 | 0.160 |
Why?
| | Hormones | 1 | 2021 | 138 | 0.160 |
Why?
| | Osteitis Deformans | 1 | 2020 | 8 | 0.160 |
Why?
| | Fractures, Compression | 1 | 2020 | 15 | 0.160 |
Why?
| | Osteolysis | 1 | 2020 | 18 | 0.160 |
Why?
| | Self Administration | 1 | 2020 | 125 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2053 | 0.150 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 21 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 1054 | 0.150 |
Why?
| | Health Services for the Aged | 1 | 2019 | 73 | 0.150 |
Why?
| | Bone and Bones | 1 | 2021 | 314 | 0.140 |
Why?
| | Self Report | 1 | 2023 | 871 | 0.140 |
Why?
| | Pyrazoles | 2 | 2013 | 490 | 0.140 |
Why?
| | Hip Fractures | 1 | 2019 | 85 | 0.140 |
Why?
| | Pyridines | 2 | 2013 | 567 | 0.140 |
Why?
| | House Calls | 1 | 2020 | 147 | 0.140 |
Why?
| | Spinal Stenosis | 1 | 2018 | 31 | 0.140 |
Why?
| | Anorexia Nervosa | 1 | 2019 | 78 | 0.140 |
Why?
| | Back Pain | 1 | 2018 | 52 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2025 | 16626 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2023 | 822 | 0.130 |
Why?
| | Progesterone | 1 | 2019 | 258 | 0.130 |
Why?
| | HIV Infections | 1 | 2012 | 3003 | 0.130 |
Why?
| | Anesthetics, Local | 1 | 2018 | 102 | 0.130 |
Why?
| | Middle Aged | 14 | 2025 | 35049 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 278 | 0.130 |
Why?
| | Pelvic Bones | 1 | 2019 | 129 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2023 | 8020 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2013 | 927 | 0.120 |
Why?
| | Curriculum | 1 | 2023 | 1042 | 0.120 |
Why?
| | Primary Health Care | 2 | 2023 | 1768 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1501 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2019 | 496 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 502 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 952 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5994 | 0.090 |
Why?
| | Hirsutism | 1 | 2011 | 12 | 0.090 |
Why?
| | Quality of Life | 2 | 2021 | 3064 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1661 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2167 | 0.090 |
Why?
| | Prevalence | 2 | 2019 | 2817 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2010 | 203 | 0.080 |
Why?
| | Imidazoles | 1 | 2010 | 251 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 807 | 0.070 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 453 | 0.070 |
Why?
| | Pituitary Hormones | 1 | 2008 | 16 | 0.070 |
Why?
| | Amenorrhea | 1 | 2008 | 31 | 0.070 |
Why?
| | Kisspeptins | 1 | 2007 | 6 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 367 | 0.070 |
Why?
| | Endocrine Glands | 1 | 2007 | 15 | 0.070 |
Why?
| | Thyroid Hormones | 1 | 2008 | 68 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 566 | 0.070 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 7 | 0.060 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 38 | 0.060 |
Why?
| | Prolactin | 1 | 2007 | 92 | 0.060 |
Why?
| | Hypothalamus | 1 | 2007 | 154 | 0.060 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 140 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1128 | 0.060 |
Why?
| | Thyrotropin | 1 | 2007 | 116 | 0.060 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 147 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2826 | 0.060 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2007 | 219 | 0.060 |
Why?
| | Calcitriol | 1 | 2025 | 58 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 327 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5700 | 0.060 |
Why?
| | Parathyroid Hormone | 1 | 2025 | 111 | 0.060 |
Why?
| | Young Adult | 3 | 2025 | 13878 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2024 | 79 | 0.050 |
Why?
| | Endocrinologists | 1 | 2024 | 13 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2024 | 252 | 0.050 |
Why?
| | Pituitary-Adrenal System | 1 | 2024 | 164 | 0.050 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2022 | 25 | 0.050 |
Why?
| | Paroxetine | 1 | 2000 | 9 | 0.040 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2000 | 48 | 0.040 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2020 | 9 | 0.040 |
Why?
| | RANK Ligand | 1 | 2020 | 29 | 0.040 |
Why?
| | Calcium | 1 | 2025 | 1179 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1999 | 83 | 0.040 |
Why?
| | Double-Blind Method | 3 | 2018 | 2007 | 0.040 |
Why?
| | Nicotinic Agonists | 1 | 2000 | 136 | 0.040 |
Why?
| | Calcium, Dietary | 1 | 2019 | 56 | 0.040 |
Why?
| | Health Status Indicators | 1 | 1999 | 161 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1053 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2025 | 11298 | 0.040 |
Why?
| | Triamcinolone | 1 | 2018 | 13 | 0.040 |
Why?
| | Health Status | 1 | 2024 | 822 | 0.040 |
Why?
| | Tobacco Use Disorder | 1 | 2000 | 237 | 0.040 |
Why?
| | Injections, Epidural | 1 | 2018 | 28 | 0.040 |
Why?
| | Adolescent | 2 | 2019 | 22326 | 0.040 |
Why?
| | Betamethasone | 1 | 2018 | 21 | 0.040 |
Why?
| | Risk Factors | 1 | 2012 | 10593 | 0.040 |
Why?
| | Methylprednisolone | 1 | 2018 | 64 | 0.030 |
Why?
| | Lidocaine | 1 | 2018 | 55 | 0.030 |
Why?
| | United States | 2 | 2025 | 15447 | 0.030 |
Why?
| | Nicotine | 1 | 2000 | 340 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2019 | 188 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2831 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2000 | 434 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1328 | 0.030 |
Why?
| | Eating | 1 | 2019 | 397 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1996 | 142 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 377 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 556 | 0.030 |
Why?
| | Vitamin D | 1 | 2019 | 401 | 0.030 |
Why?
| | Body Composition | 1 | 2019 | 706 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1471 | 0.030 |
Why?
| | Pain Management | 1 | 2018 | 401 | 0.030 |
Why?
| | Signal Transduction | 1 | 2007 | 5163 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1144 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 4207 | 0.020 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 53 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 28 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 53 | 0.020 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 187 | 0.020 |
Why?
| | Serum Albumin | 1 | 2013 | 148 | 0.020 |
Why?
| | Ethanol | 1 | 1996 | 637 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 1 | 2013 | 247 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 353 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 222 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1996 | 849 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 676 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 649 | 0.020 |
Why?
| | Patient Compliance | 2 | 2000 | 613 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 824 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3604 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 2093 | 0.010 |
Why?
| | Animals | 1 | 2007 | 37697 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3184 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2406 | 0.010 |
Why?
| | Administration, Cutaneous | 1 | 2000 | 128 | 0.010 |
Why?
| | Sampling Studies | 1 | 1999 | 103 | 0.010 |
Why?
| | Sickness Impact Profile | 1 | 1999 | 59 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2013 | 2568 | 0.010 |
Why?
| | North Carolina | 1 | 1999 | 122 | 0.010 |
Why?
| | Hospitals, Veterans | 1 | 1999 | 255 | 0.010 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2000 | 181 | 0.010 |
Why?
| | Health Care Surveys | 1 | 1999 | 562 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1313 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1996 | 37 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1996 | 580 | 0.010 |
Why?
| | Depression | 1 | 2000 | 1503 | 0.010 |
Why?
|
|
Rothman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|